Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 2, 1999, Pages 105-110

  Britten, Carolyn D ^a   Izbicka, Elzbieta ^a   Hilsenbeck, Susan ^a   Lawrence, Richard ^a   Davidson, Karen ^a   Cerna, Caeser ^a   Gomez, Lionel ^a   Rowinsky, Eric K ^a   Weitman, Steven ^a   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

Human tumor cloning assay; LY231514; Multitargeted antifolate

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLIC ACID ANTAGONIST; IRINOTECAN; PACLITAXEL; PEMETREXED;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COLONY FORMING UNIT; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; TUMOR STEM CELL ASSAY;

EID: 0032990562     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050953     Document Type: Article

References (28)

1. 1. Allegra CJ, Grem JL (1997) Antimetabolites. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology. 5th edn. Lippincott-Raven Publishers, Philadelphia New York, p 342
2. 2. Clarke S, Boyer M, Millward M, Findlay M, Ackland S, Childs A, Brew S, Walcher V, Watt D, Campbell L (1998) Multitargeted antifolate MTA (LY231514): an active agent in advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 17: 466a
3. 3. Cripps MC, Burnell M, Jolivet J, Lofters W, Fisher B, Panasci L, Iglesias J, Eisenhauer E (1997) Phase II study of a multitargeted antifolate (LY231514) as first-line therapy in patients with locally advanced or metastatic colorectal cancer (abstract). Proc Am Soc Clin Oncol 16: 267a
4. 4. Foulke RS, Marshall MH, Trotta PP, Von Hoff DD (1990) In vitro assessment of the effects of granulocyte-macrophage colony stimulating factor on primary human tumors and derived lines. Cancer Res 50: 6264
5. 5. Grindey GB, Shih C, Barnett CJ, Pearce HL, Engelhardt JA, Todd GC, Rinzel SM, Worzalla JF, Gossett LS, Everson TP, Wilson TM, Kobierski ME, Winter MA, Bewley JR, Kuhnt D, Taylor EC, Moran RG (1992) LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (abstract). Proc Am Assoc Cancer Res 33: 411
6. 6. Hamburger A, Salmon SE (1977) Primary bioassay of human myeloma stem cells. J Clin Invest 60: 846
7. 7. Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197: 461
8. 8. Hammond L, Villalona-Calero M, Eckhardt SG, Drengler R, Aylesworth C, Johnson T, Hidalgo M, Rodriguez G, Diab S, Monroe P, Thornton D, Von Hoff D, Rowinsky E (1998) A phase I and pharmacokinetic study of the multitargeted antifolate (MTA) LY231514 with folic acid (abstract). Proc Am Soc Clin Oncol 17: 225a
9. 9. Hanauske AR, Hilsenbeck SG, Von Hoff DD (1997) Human tumor screening. In: Teicher B (ed) Anticancer drug development guide: preclinical screening, clinical trials, and approval. Humana Press, Totowa, NJ, p 43
10. 10. John W, Picus J, Blanke C, Clark J, Shulman L, Rowinsky E, Thornton D, Loehrer PJ (1998) Activity of MTA (LY231514) in patients with advanced colorectal cancer - results from a phase II study (abstract). Proc Am Soc Clin Oncol 17: 277a
11. 11. Lind MJ, Smith IE, Coleman RE, Calvert AH, Patel M, Miles DW (1998) Phase II study of MTA (LY231514) in patients with locally recurrent or metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 17: 112a
12. 12. Miller KD, Loehrer PJ, Picus J, Blanke C, John W, Clark J, Shulman L, Burris H, Thornton D (1997) A phase II trial of LY231514 in patients with unresectable pancreatic cancer (abstract). Proc Am Soc Clin Oncol 16: 297a
13. 13. Paz-Ares L, Tabernero J, Moyano A, Rifa J, Gomez H, Marcuello E, Gonzlez A, Trazona I, Cortes-Funes H (1998) A phase II study of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma of the bladder (abstract). Proc Am Soc Clin Oncol 17: 339a
14. 14. Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langley C, Clark G, Faries D, Lu P, Von Hoff DD (1995) Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13(11): 2842
15. 15. Rinaldi DA, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Fields SM, Woodworth JR, Kuhn JG, Langley C, Clark G, Lu P, Von Hoff DD (1995) A phase I evaluation of LY231514, a novel multitargeted antifolate, administered every 21 days (abstract). Proc Am Soc Clin Oncol 15: 489
16. 16. Rusthoven J, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J (1997) A phase II study of the multi-targeted antifolate LY231514 in patients with advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 16: 480a
17. 17. Salmon SE, Liu R (1989) Effects of granulocyte-macrophage colony stimulating factor on in vitro growth of human solid tumors. J Clin Oncol 7: 3146
18. 18. Sauter T, Boucsein G, Thoedtmann R, Miller K, Ohnmacht U, Blatter J, Hanauske AR (1998) Multicenter phase II trial of MTA in chemonaive patients with metastatic renal cancer (abstract). Proc Am Soc Clin Oncol 17: 342
19. 19. Schultz RM, Patel VF, Worzalla JF, Shih C (1998) Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate (abstract). Proc Am Assoc Cancer Res 39: 434
20. 20. Shih C, Grindey GB, Barnett CJ, Pearce HL, Engelhardt JA, Todd GC, Rinzel SM, Worzalla JF, Gossett LS, Everson TP, Wilson TM, Kobierski ME, Winter MA, Kuhnt D, Taylor EC, Moran RG (1992) Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514 (abstract). Proc Am Assoc Cancer Res 33: 411
21. 21. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116
22. 22. Shoemaker RH, Wopert-DeFilippes MK, Kern DH, Lieber MM, Makuch RW, Melnick NR, Miller WT, Salmon SE, Simon RM, Venditti JM, Von Hoff DD (1985) Application of a human tumor colony-forming assay to new drug screening. Cancer Res 45: 2145
23. 23. Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, Jannatipour M, Moran RG (1992) A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35: 4450
24. 24. Thoedtmann R, Kemmerich M, Depenbrock H, Blatter J, Ohnmacht U, Hanauske AR (1998) A phase I study of MTA plus cisplatin in patients with advanced solid tumours (abstract). Proc Am Soc Clin Oncol 17: 254a
25. 25. Von Hoff DD (1990) He's not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 82: 96
26. 26. Von Hoff DD, Coltman CA, Forseth B (1981) Activity of mitoxantrone in a human tumor cloning system. Cancer Res 41: 1853
27. 27. Von Hoff DD, Forseth BJ, Huong M, Buchok JB, Lathan B (1986) Improved plating efficiencies for human tumors cloned in capillary tubes versus petri dishes. Cancer Res 46: 4012
28. 28. Von Hoff DD, Huong AM, Collins J (1988) Effect of recombinant beta Interferon (r-IFN-βser) on primary human tumor colony forming units. J Interferon Res 8: 813